ArticleGenes & nutrition2025
The ameliorative effect of pioglitazone and/or cod liver oil on hepatotoxicity induced by carbon tetrachloride in rats.
Article in Genes & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimization of a fresh fecal intraperitoneal injection sepsis model and its divergent dynamics from cecal ligation and puncture in mice.Laboratory animal research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver diseases rank among the foremost causes of mortality and morbidity worldwide. The PPARγ ligand, pioglitazone (PG), which has been clinically tested and is utilized in diabetes management, demonstrated a hepatoprotective effect in different studies. Furthermore, cod liver oil (COD) and its components exhibit a significant protective effect against hepatotoxicity in animals. This work aimed to investigate the impact of PG and/or COD on hepatotoxicity provoked by carbon tetrachloride (CCl4) in rats. Fifty albino Wistar rats were assigned to five groups (n = 10). Group I acted as a control. Group II received CCl4. Groups III and IV were administered with CCl4 and co-treated with oral PG or COD, respectively. Group V was administered with CCl4 and co-treated with both PG and COD. The duration of the experiment was 4 weeks. Liver function tests, hyaluronic acid (HA), and adiponectin levels were measured in serum. In liver tissue, adiponectin, tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10) gene expressions were evaluated by RT-PCR. Moreover, histopathological examinations and alpha-smooth muscle actin (α-SMA) immunoreactivity were assessed in hepatic tissues. Histopathological alterations were improved in the group treated with combined PG and COD, as indicated by amelioration of liver function tests, as well as decreased HA and elevated adiponectin levels in serum. In hepatic tissues, there was also an upregulation of adiponectin and IL-10 and a downregulation of TNF-α gene expression. Moreover, PG and COD decreased α-SMA expression in hepatic tissues as well. These findings indicate that PG and/or COD markedly mitigate liver damage caused by CCl4 in rats; however, further large-scale studies are necessary to prove this hypothesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.